Analysts project $30 billion in retatrutide revenue by 2031 as Lilly plans early 2027 filing

Clarivate analysts estimate that retatrutide, Eli Lilly's experimental triple-hormone treatment for obesity and diabetes, could bring in about $30 billion in revenue by 2031, split into roughly $10 billion from obesity and $20 billion from diabetes ^[1]. Lilly plans to file a Biologics License Application for the drug in the first quarter of 2027, with a launch window in 2028 ^[1].

Retatrutide acts on three hormone receptors: GIP, GLP-1 and glucagon ^[1]. In Phase 3 testing, a 12 mg dose produced an average weight loss of 70.3 pounds, or 28.3%, over 80 weeks in participants with obesity ^[1]. The drug is not approved for sale in the United States, and no price or insurance coverage terms have been disclosed.

The same forecast places orforglipron, the oral GLP-1 tablet Lilly sells as Foundayo, at about $16 billion in sales by 2031 ^[1]. One report says orforglipron is already approved and generated $98 million in its first reported quarter ^[1]. Another report published days earlier lists the pill among pipeline candidates whose Phase 3 data and market launch are still ahead ^[2]. That account also notes that oral drugs can carry tolerability problems that injectables do not ^[2].

Market sizing keeps moving in one direction. A few years ago, a common Wall Street estimate for the global obesity drug market in 2030 was around $50 billion a year, then $100 billion; the midpoint of published forecasts now sits near $130 billion, with more aggressive estimates at $150 billion ^[2]. Those revisions follow data showing benefits beyond weight loss, including cardiovascular, sleep apnea and kidney outcomes, which expand the population insurers and doctors are willing to treat ^[2].

Lilly's current products are the base those projections build on. Tirzepatide, sold as Zepbound for weight loss and Mounjaro for diabetes, generated $15.7 billion in key product revenue in the second quarter of 2026, with Zepbound up 46% and Mounjaro up 91% from a year earlier ^[1].

Capacity is the other half of the bet. Lilly's capital spending reached $9.9 billion over the trailing twelve months, largely to build the manufacturing the forecasts assume ^[1]. The company carries $108.4 billion in total debt and $46 billion in net debt ^[1]. One analysis calls the balance sheet "passable, but not strong" and warns that slower-than-expected manufacturing or clinical setbacks would amplify the financial risk ^[1]. Lilly has committed tens of billions of dollars to plants in the United States and Europe, which holds back near-term margin expansion, according to another view ^[2].

Risks cited include regulator scrutiny of muscle loss and long-term safety with more potent drugs, and competition from Novo Nordisk, which has its own oral and combination candidates in trials ^[2]. Lilly stock trades at 62.8 times forward earnings, against 10.8 times trailing earnings for Novo Nordisk ^[1]. Lilly shares fell 8% over the 20 days before one report, from a 52-week high of $1,293 ^[1].

Why it matters for patients

Revenue forecasts do not set what patients pay. They signal how much manufacturing capacity, sales effort and insurer negotiation the companies expect around these drugs, which can shape supply and formulary decisions over time.

More options may be coming. Retatrutide is designed as a weekly injection, while orforglipron is a pill, and pills are easier to manufacture at scale and distribute globally than shots, addressing what one analysis calls the category's biggest supply bottleneck ^[2]. Whether that leads to broader access or lower out-of-pocket costs has not been reported.

Safety questions remain open. Regulators are expected to scrutinize muscle loss and long-term safety with more potent drugs ^[2]. Whether retatrutide's Phase 3 program addressed those concerns, and what its label would say, has not been disclosed.

A 2028 launch is a projection, not a guarantee. Lilly still has to file, and the Food and Drug Administration still has to review.

What happens next

• First quarter of 2027: Lilly plans to submit the retatrutide application ^[1].
• 2028: the projected launch window for retatrutide, if it is approved ^[1].
• Over the 18 months from September 2026: several pipeline readouts are due, and one analysis warns a single disappointing result could sharply move the stock ^[2].
• Full-year orforglipron sales have not been reported; the $98 million figure covers its first reported quarter ^[1].